Copper(II) complexes of methimazole, an anti Grave's disease drug. Synthesis, characterization and its potential biological behavior as alkaline phosphatase inhibitor.
Methimazole (MeimzH) is an anti-thyroid drug and the first choice for patients with Grave's disease. Two new copper(II) complexes of this drug: [Cu(MeimzH)(2)(NO(3))(2)]*0.5H(2)O and [Cu(MeimzH)(2)(H(2)O)(2)](NO(3))(2)*H(2)O were synthesized and characterized by elemental analysis, dissolution behavior, thermogravimetric analysis and UV-vis, diffuse reflectance, FTIR and EPR spectroscopies. As it is known that copper(II) cation can act as an inhibitor of alkaline phosphatase (ALP), the inhibitory effect of methimazole and its copper(II) complexes on ALP activity has also been investigated.
Urquiza
Nora M
NM
Cátedra de Química Analítica, Instituto de Química Analítica, Facultad de Bioquímica, Química y Farmacia, Universidad Nacional de Tucumán, 4000 San Miguel de Tucumán, Argentina.
Manca
Silvia G
SG
Moyano
María A
MA
Dellmans
Raquel Arrieta
RA
Lezama
Luis
L
Rojo
Teófilo
T
Naso
Luciana G
LG
Williams
Patricia A M
PA
Ferrer
Evelina G
EG
D000469:Alkaline Phosphatase / Q000037:antagonists & inhibitors*; D000818:Animals; D013956:Antithyroid Agents / Q000138:chemical synthesis* / Q000737:chemistry / Q000378:metabolism* / Q000627:therapeutic use*; D003300:Copper / Q000737:chemistry*; D004578:Electron Spin Resonance Spectroscopy; D006111:Graves Disease / Q000188:drug therapy*; D006801:Humans; D008713:Methimazole / Q000138:chemical synthesis* / Q000737:chemistry / Q000378:metabolism* / Q000627:therapeutic use*; D013056:Spectrophotometry, Ultraviolet; D017550:Spectroscopy, Fourier Transform Infrared
D013956:Antithyroid Agents; D008713:Methimazole; D003300:Copper; D000469:Alkaline Phosphatase